Selecting & Optimizing State-of-the-Art, Predictive, & Cost-Effective Models to Enhance Target Selection, Facilitate Biomarker Discovery & Achieve Clinical Translatability
Welcome to Tumour Models Summit Nordics
The First and Only Summit Dedicated to Networking & Discussing New Trends in Tumour Models in the Nordics
The inherent heterogeneity of cancer - both inter-patient and intra-tumoral – remains a significant challenge in cancer modeling. With only 5% of cancer drugs successfully advancing to clinical trials, there is a critical need for more accurate and predictive models to guide therapeutic development.
For the first time, the Tumour Models Summit Nordics unites pharma, biotech, and research leaders across the thriving Nordic biotech ecosystem to tackle this challenge head-on. As the region’s only industry-led event of its kind, this summit provides a rare opportunity to connect with top experts in preclinical and translational research.
Gain insights into the cutting-edge innovation in in vivo and in vitro tumour modelling, discover strategies to de-risk your studies, and learn how to refine your drug development pipeline. Join us to engage with decision-makers, explore ground breaking solutions, and accelerate the path from lab to patient in today’s rapidly evolving landscape.
Why Attend?
This summit offers a focused exploration of the most critical topics in tumour modelling through dynamic discussion, actional case studies, and expert insights. Key highlights include:
Leverage Cutting-Edge 3D in vitro models with Roche: Understand how 3D infiltration platforms can effectively evaluate immunotherapy modes of action and explore comparisons to in vivo
Target/Receptor Axis Modelling with Anocca: Explore engineered T-cells for systematic determination of target/receptor activity
Humanised Mouse Models with BioInvent: Investigate the potential of single and double humanised mouse models for bispecific development
Advanced Omics Data with Curacell: Unlock mechanisms of action using cell sequencing technologies to refine therapeutic protocols
Treating Solid Tumours with Hemispherian: Discover innovative DNA-targeting mechanisms to selectively kill cancer cells
Meet the Experts
Mette Trauelsen
Chief Executive Officer
SOLID Therapeutics
Adam Robertson
Chief Scientific Officer
Hemispherian
Lucas Arruda
Chief Scientific Officer
Curacell
Jette Lange
Director of Non-Clinical Department
Adcendo
Santiago Parpal
Principal Scientist
Sprint Bioscience
Carl Sandén
Chief Scientific Officer
Lead Biologics
What Past Attendees say about the Tumor Models Series
"This summit included the most cutting-edge achievements and potential collaborations in the scientific and industrial world”
Roche
“Cutting edge presentations on innovations in translational biology of several cancers and opportunities to have independent discussions with CROs”
Aperion Therapeutics
“It is such a pleasure to meet experts in the field of IO tumour models. This is a tricky field and sharing the challenges we are experiencing accelerates development of these paradigm-changing therapies”
Astellas
“The programme of presentations was rich and varied. Presentation time was also good (not too short or too long). The size of the event was favourable for networking”
Johnson & Johnson
“The conference exceeded my expectations. The talks were very relevant to my day-to-day work as in vivo scientist in a cell therapy company. I enjoyed the networking; attendees were very approachable”
Arsenal Biosciences
Expertise Partner
Other Events in the Series
